Comparison of Two Preoperative Antiseptic Solutions Alcohol Based in Abdominal Elective Surgeries

Surgical Site Infection Clinical Trial

Official title:

Iodine-Povidone Alcohol Compared to Chlorhexidine Alcohol as Preoperative Antiseptics in Major Abdominal Elective Clean Contaminated Surgery

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03859908
• Other study ID #: Iodine alcohol Trial
• Secondary ID: CNEIS/2018/049
• Status: Terminated
• Phase: Phase 4
• Start date: April 5, 2019
• Est. completion date: January 27, 2021

Study information

• Verified date: May 2023
• Source: Universidad de El Salvador
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pragmatic randomized clinical trial comparing Iodine Povacrylex based on alcohol to Chlorhexidine also based on alcohol in efficacy and security to diminish frequency of surgical site infections in major abdominal elective clean contaminated wounds. Will be held in a third level university, high volume national public hospital in San Salvador, El Salvador.

Description:

Preoperative antiseptic Chlorhexidine based on alcohol has been established as gold standard of care for clean contaminated wounds. It was compared to Iodine solutions non-alcohol based. There is a question about alcohol based solution was a confounder in the comparison. The aim of this study is to compare the efficacy of both solutions alcohol based, 0.7% iodine povacrylex plus 74% alcohol, against gluconate chlorhexidine 2% plus 70% alcohol, in clean contaminated wounds, in major abdominal elective surgeries, in a wider range than colorectal surgeries, Materials and methods. With a pragmatic randomized, phase 4, controlled clinical trial. Comparison of two antiseptic solutions, using manufacturer (3M) sterile appliers' for both products, Food and Drugs Agency approved. Quality of data will be assured by first training all surgeons and residents besides researchers in the study protocol for protocol compliance in subject identification, randomization moment, and follow up. There is a plan for weekly monitoring of protocol compliance, and monthly data monitoring and auditing from Faculty of Medicine Research Unit. Monitoring and auditing will comply protocol compliance and data integrity against subject's medical records and random interviews of patients in their post-surgical control. Surgical Site Infection definitions are those taken from Centers for Disease Control definitions. Standard Operating Procedures will be established in all moments of the trial, from subject identification, informed consent, recruitment, randomization process in the operating room, and data collection in pre specified files for data collection and data management. Protocol compliance and Standard Operating Procedures compliance will be monitored by Principal Investigator constantly. Report of adverse events will be done in accordance to Salvadoran National ethics committee Standard Operating Procedures as also any other communication such as protocol deviance or amendments. Previous research has not reported adverse events, but we will be expectant to their appearance. Sample size was calculated for a total of 964 subjects, 482 in each group, using statistics software, were we established a statistic significant level for a bilateral hypothesis of 95% and a power of 80%, based on previous research of comparison of both solutions to get a probability of SSI of 4.2% in Chlorhexidine group against 8.6% in Iodine povacrylex group. We will establish a strict follow up of patients in the 30 days considered as post-operative time, by enabling the whole public health system to integrate in subjects´, surgical care (primary care) to diminish the probability of missing data. Data analysis will be done following "intention to treat" analysis principle. Primary outcome will be any kind of Surgical Site Infection, categorical variable, will be analyzed with chi square for a bilateral hypothesis, and also measure the difference with risk ratio and its 95% confidence interval.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 18
• Est. completion date: January 27, 2021
• Est. primary completion date: January 27, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Elective surgery categorized as clean contaminated surgery Major abdominal -

Exclusion Criteria:

• American Society of Anesthesia III-IV
• Laparoscopic cholecystectomy
• Inguinal hernias classification I, II
• Obese subjects with Body Mass Index more than 35 or malnourished
• immunocompromised subjects
• neoplasia Preoperative hospital stay more than 7 days allergic to any of the solutions used in the trial

Related Conditions & MeSH terms

• Surgical Site Infection
• Surgical Wound Infection

Intervention

Drug:
• Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML
As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
• Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML
As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis

Locations

Country	Name	City	State
El Salvador	Hospital Nacional Rosales	San Salvador

Sponsors (1)

Lead Sponsor	Collaborator
Universidad de El Salvador

Country where clinical trial is conducted

El Salvador, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Surgical site infection	infections of the incision or organ or space that occur after surgery.	Date of event occurs within 30 days after any operative procedure (where day 1 = the procedure date)
Secondary	Superficial surgical site infection	Infection that occurs after surgery and involves only skin and subcutaneous tissue of the incision	Date of event occurs within 30 days after any operative procedure (where day 1 = the procedure date)
Secondary	Deep surgical site infection	Infection that occurs after surgery that involves deep soft tissues of the incision (for example, fascial and muscle layers)	Date of event occurs within 30 days after any operative procedure (where day 1 = the procedure date)
Secondary	Organ/space SSI	Infection that occurs after surgery that involves any part of the body deeper than the fascial/muscle layers that is opened or manipulated during the operative procedure	Date of event occurs within 30 days after any operative procedure (where day 1 = the procedure date)
Secondary	Skin reaction	Any kind of irritation or skin reaction after applying the solution	Date of event occurs within 7 days after surgery (where day 1= the procedure date